Objective: The study aimed to investigate the role of N6-methyladenosine (m6A) modification in spinal cord injury (SCI) and its underlying mechanism, focusing on the interplay between m6A methyltransferase-like 3 (METTL3), miR-30c, and autophagy-related proteins.Methods: An SCI model was established in rats, and changes in autophagy-related proteins, m6A methylation levels, and miR-30c levels were analyzed. Hydrogen peroxide (H2O2)-stimulated spinal cord neuron cells (SCNCs) were used to assess the impact of METTL3 overexpression. The effects of STM2457, an antagonist of METTL3, were evaluated on cell viability, apoptosis, and autophagy markers in H2O2-stimulated SCNCs.Results: In the SCI model, decreased levels of autophagy markers and increased m6A methylation, miR-30c levels, and METTL3 were observed. Overexpression of METTL3 in SCNCs led to reduced cell viability, increased apoptosis, and suppressed autophagy. Conversely, co-overexpression of autophagy-related protein 5 (ATG5) or miR-30c inhibition reversed these effects. Knocking out METTL3 yielded opposite results. STM2457 treatment improved cell viability, reduced apoptosis, and upregulated autophagy markers in SCNCs, which also enhanced functional recovery in rats as measured by the Basso-Beattie-Bresnahan score and inclined plate test.Conclusion: STM2457 alleviated SCI by suppressing METTL3-mediated m6A modification of miR-30c, which in turn induces ATG5-mediated autophagy. This study provides insights into the role of m6A modification in SCI and suggests a potential therapeutic approach through targeting METTL3.
Background: Spinal cord injury (SCI) often leads to neuropathic pain (NeP), severely impacting patients’ function and rehabilitation. Vitamin D deficiency, highly prevalent in SCI due to reduced sun exposure and mobility, has been implicated in NeP in other conditions, but its role in chronic SCI-related NeP remains unclear. Methods: This cross-sectional study enrolled 182 adults with chronic traumatic SCI (≥6 month post-injury) currently admitted to 2 rehabilitation centers. Vitamin D status {serum 25-hydroxyvitamin D [25(OH)D]} was measured via high-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/MS). NeP was diagnosed using the Douleur Neuropathique 4 (DN4) questionnaire (score ≥4/10) in combination with clinical assessment by a physician. Multivariate logistic regression, controlling for confounders (e.g., age, comorbidity, Charlson Comorbidity Index, CCI), injury severity (American Spinal Injury Association Impairment Scale, and AIS grade), assessed the association between vitamin D levels and NeP. Receiver operating characteristic (ROC) curve analysis was performed to identify a predictive cutoff. Results: The prevalence of NeP was 52.7% (96/182). Vitamin D deficiency or insufficiency [25(OH)D < 30 ng/mL] affected 64.8% (118/182) of participants. Lower vitamin D levels were strongly and independently associated with NeP risk. Individuals in the lowest vitamin D tertile (2.00–11.68 ng/mL) had significantly higher adjusted odds of NeP compared to those in the highest tertile (16.71–23.03 ng/mL) [adjusted odds ratio: 4.8, 95% CI: (3.4, 6.8), p < 0.001]. ROC analysis identified a serum 25(OH)D level <16.35 ng/mL as a predictive cutoff for NeP (area under the curve = 0.812, sensitivity 79.1%, specificity 71.9%). Conclusion: Vitamin D deficiency is highly prevalent and a strong, independent predictor of neuropathic pain in individuals with chronic SCI. These cross-sectional findings suggest routine screening for vitamin D deficiency might be indicated; however, interventional trials are needed to confirm a potential therapeutic role of vitamin D supplementation in managing SCI-related NeP.
Sarcopenia in chronic obstructive pulmonary disease (COPD) is driven by elevated tumor necrosis factor‐alpha (TNF‐α), yet the underlying mechanism remains unclear. Here, we identify the mitochondrial metabolic enzyme Prodh2 as a pivotal mediator. Prodh2 was significantly upregulated in sarcopenic COPD patients and a corresponding mouse model. Mechanistically, TNF‐α induced Prodh2 transcription in myoblasts via a p53‐dependent pathway. This upregulation triggered excessive mitochondrial reactive oxygen species, leading to the release of mitochondrial DNA (mtDNA). Cytosolic mtDNA subsequently activated the cGAS/STING innate immune pathway, causing myoblast apoptosis, proliferation arrest, and atrophy. While Prodh2 knockdown reversed these effects in vitro, muscle‐specific knockdown of Prodh2 in vivo critically ameliorated muscle atrophy and restored strength. Our study unveils a novel TNF‐α‐p53‐Prodh2‐cGAS/STING axis that links chronic inflammation to sarcopenia through metabolic‐immune crosstalk, validating Prodh2 as a promising therapeutic target.
30 April 2026 in Frontiers in Molecular Biosciences
Background: Sarcopenia, an age-correlated decline in skeletal muscle mass and function, has been increasingly linked to ferroptosis, which is an iron-dependent form of regulated cell death driven by lipid peroxidation. Nevertheless, the diagnostic potential and mechanistic role of ferroptosis-relevant genes (FRGs) in sarcopenia remains poorly understood. Methods: We integrated bioinformatics analyses and experimental validation to identify and characterize key FRGs in sarcopenia. By employing RNA-seq data from public datasets (GSE25941 and GSE9103), we identified differentially expressed FRGs and applied weighted gene co-expression network analysis (WGCNA) and multiple machine learning algorithms (comprising LASSO, SVM, KNN, XGBoost, and NNET) to screen for diagnostic biomarkers. Results: Six hub FRGs ( ACSL6 , CDKN1A , ATG4D , DECR1 , HSF1 , and MIB1 ) were identified with AUC>0.8 as robust diagnostic biomarkers, among which HSF1 exhibited the highest diagnostic value (AUC = 0.9247). Molecular docking suggested quercetin and cycloheximide as potential therapeutic agents targeting HSF1. As demonstrated by functional experiments in C2C12 myoblasts, HSF1 silencing facilitated lipid metabolism, elevated ferroptosis markers, and induced muscle atrophy, while its overexpression attenuated these effects. Conclusion: Our findings not only underscore the significance of FRGs in sarcopenia pathogenesis but also highlight their potential as diagnostic markers and therapeutic targets.